Literature DB >> 8651230

Aspirin use and cognitive function in the elderly.

T Stürmer1, R J Glynn, T S Field, J O Taylor, C H Hennekens.   

Abstract

Decline in cognitive function in the elderly is common and represents a major clinical and public health concern. Aspirin may reduce the decline in cognitive function by influencing multi-infarct dementia, but data are sparse. The East Boston Senior Health Project is a population-based cohort study that enrolled 3,809 community-dwelling residents aged 65 years and older in 1982-1983 and followed them with home visits every 3 years until 1988-1989. Trained interviewers assessed cognitive function by using the Short Portable Mental Status Questionnaire and assessed medication use, including over-the-counter drugs. Response to the Short Portable Mental Status Questionnaire was scored as high, medium, or low, and decline was defined as transition to a lower category. Participants who used drugs containing aspirin in the 2 weeks prior to the interview were classified as aspirin users. Multiple logistic regression was used to obtain adjusted odds ratios and their 95% confidence intervals for decline of cognitive function. The estimating equation approach was used to adjust the standard errors for repeated measurements. Aspirin users had an odds ratio for cognitive decline of 0.97 (95% confidence interval 0.82-1.15). Low frequency of aspirin use (less than daily) was associated with an odds ratio of 0.87 (95% confidence interval 0.69-1.09). Although no substantial effect was observed, the data are also compatible with a modest benefit of aspirin, especially with intermittent use, on decline of cognitive function. Concern about small residual biases from self-selection or confounding suggests that randomized trials will be necessary to provide definitive data on this question.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8651230     DOI: 10.1093/oxfordjournals.aje.a008801

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  13 in total

1.  Vascular cognitive impairment.

Authors:  Laura Pedelty; David L Nyenhuis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

2.  Anti-inflammatory agents and cognitive decline in a bi-racial population.

Authors:  Francine Grodstein; Kimberly A Skarupski; Julia L Bienias; Robert S Wilson; David A Bennett; Denis A Evans
Journal:  Neuroepidemiology       Date:  2008-02-07       Impact factor: 3.282

Review 3.  Drug-induced cognition disorders in the elderly: incidence, prevention and management.

Authors:  S L Gray; K V Lai; E B Larson
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

Review 4.  Nonsteroidal anti-inflammatory drugs and cognitive function: do they have a beneficial or deleterious effect?

Authors:  T M Karplus; K G Saag
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 5.  Association Between Non-Steroidal Anti-Inflammatory Drug Use and Cognitive Decline: A Systematic Review and Meta-Analysis of Prospective Cohort Studies.

Authors:  WeiJing Wang; YanPing Sun; DongFeng Zhang
Journal:  Drugs Aging       Date:  2016-07       Impact factor: 3.923

6.  Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70.

Authors:  Mark R Nelson; Danny Liew; Melanie Bertram; Theo Vos
Journal:  BMJ       Date:  2005-05-20

7.  Is there any evidence for a protective effect of antithrombotic medication on cognitive function in men at risk of cardiovascular disease? Some preliminary findings.

Authors:  M Richards; T W Meade; S Peart; P J Brennan; A H Mann
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

8.  Nonsteroidal anti-inflammatory drugs, aspirin, and cognitive function in the Baltimore longitudinal study of aging.

Authors:  Shari R Waldstein; Carrington Rice Wendell; Stephen L Seliger; Luigi Ferrucci; E Jeffrey Metter; Alan B Zonderman
Journal:  J Am Geriatr Soc       Date:  2010-01       Impact factor: 5.562

9.  Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE).

Authors:  Mark Nelson; Christopher Reid; Lawrence Beilin; Geoffrey Donnan; Colin Johnston; Henry Krum; Elsdon Storey; Andrew Tonkin; John McNeil
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Low dose aspirin and cognitive function in the women's health study cognitive cohort.

Authors:  Jae Hee Kang; Nancy Cook; JoAnn Manson; Julie E Buring; Francine Grodstein
Journal:  BMJ       Date:  2007-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.